

Audit Review Table					
Presbyterian Health Plan, Inc. (Org ID: 579, Sub ID: 4104, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2025; Date & Timestamp - 6/4/2026 2:21:45 PM					
This submission is on the stage: Submission Finalized					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
BMI percentile (Total)		62.75%	R	R	Reported
Counseling for Nutrition (Total)		22.56%	R	R	Reported
Counseling for Physical Activity (Total)		24.90%	R	R	Reported
Lead Screening in Children (LSC)					
Lead Screening in Children		49.15%	R	R	Reported
Chlamydia Screening (CHL)					
(Total)		46.74%	R	R	Reported
Oral Evaluation, Dental Services (OED)	Y				
(0-2)		33.52%	R	R	Reported
(3-5)		64.90%	R	R	Reported
(6-14)		67.20%	R	R	Reported
(15-20)		46.91%	R	R	Reported
(Total)		57.07%	R	R	Reported
Topical Fluoride for Children (TFC)					
(1-2)		11.51%	R	R	Reported
(3-4)		15.59%	R	R	Reported
(Total)		13.60%	R	R	Reported
Appropriate Testing for Pharyngitis (CWP)	Y				
(Total)		83.75%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)	Y				
Systemic Corticosteroid		62.78%	R	R	Reported
Bronchodilator		74.59%	R	R	Reported
Asthma Medication Ratio (AMR)	Y				
(Total)		69.34%	R	R	Reported
Controlling High Blood Pressure (CBP)					
Controlling High Blood Pressure		48.45%	R	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	Y				
Persistence of Beta-Blocker Treatment After a Heart Attack		43.59%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)	Y				
Received Statin Therapy (Total)		65.18%	R	R	Reported
Statin Adherence 80% (Total)		73.96%	R	R	Reported
Cardiac Rehabilitation (CRE)					
Initiation (Total)		2.67%	R	R	Reported
Engagement1 (Total)		4.00%	R	R	Reported
Engagement2 (Total)		4.00%	R	R	Reported
Achievement (Total)		1.60%	R	R	Reported
Glycemic Status Assessment for Patients With Diabetes (GSD)					
Glycemic Status <8.0%		54.26%	R	R	Reported
Glycemic Status >9.0%		37.71%	R	R	Reported
Blood Pressure Control for Patients With Diabetes (BPD)					
Blood Pressure Control for Patients With Diabetes		48.92%	R	R	Reported
Eye Exam for Patients With Diabetes (EED)					
Eye Exam for Patients With Diabetes		52.49%	R	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)					
(Total)		41.26%	R	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y				
Received Statin Therapy		52.05%	R	R	Reported
Statin Adherence 80%		72.22%	R	R	Reported
Diagnosed Mental Health Disorders (DMH)					
(Total)		31.07%	R	R	Reported
Follow-Up After Hospitalization for Mental Illness (FUH)	Y				
30 days (Total)		67.51%	R	R	Reported
7 days (Total)		45.18%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y				
30 days (Total)		52.06%	R	R	Reported
7 days (Total)		33.24%	R	R	Reported
Diagnosed Substance Use Disorders (DSU)					
Alcohol (Total)		5.01%	R	R	Reported
Opioid (Total)		4.69%	R	R	Reported
Other (Total)		5.91%	R	R	Reported
Any (Total)		11.64%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)	Y				

30 days (Total)		55.39%	R	R	Reported
7 Days (Total)		29.92%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use (FUA)	Y				
30 days (Total)		36.78%	R	R	Reported
7 days (Total)		24.84%	R	R	Reported
Pharmacotherapy for Opioid Use Disorder (POD)	Y				
(Total)		26.58%	R	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	Y				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications		81.95%	R	R	Reported
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)					
Diabetes Monitoring for People With Diabetes and Schizophrenia		71.06%	R	R	Reported
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)					
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia		75.86%	NA	R	Reported
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia		57.71%	R	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)	Y				
(Total)		87.48%	R	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	Y				
(Total)		58.28%	R	R	Reported
Use of Imaging Studies for Low Back Pain (LBP)					
(Total)		65.75%	R	R	Reported
Use of Opioids at High Dosage (HDO)	Y				
Use of Opioids at High Dosage		2.66%	R	R	Reported
Use of Opioids From Multiple Providers (UOP)	Y				
Multiple Prescribers		15.70%	R	R	Reported
Multiple Pharmacies		1.50%	R	R	Reported
Multiple Prescribers and Multiple Pharmacies		0.90%	R	R	Reported
Risk of Continued Opioid Use (COU)	Y				
>=15 Days (Total)		5.62%	R	R	Reported
>=31 Days (Total)		3.63%	R	R	Reported
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
(Total)		77.93%	R	R	Reported
Initiation and Engagement of Substance Use Disorder Treatment (IET)	Y				
Initiation of SUD Treatment - Total (Total)		51.79%	R	R	Reported
Engagement of SUD Treatment - Total (Total)		20.44%	R	R	Reported
Prenatal and Postpartum Care (PPC)					
Timeliness of Prenatal Care		75.67%	R	R	Reported
Postpartum Care		76.40%	R	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Y				
(Total)		61.13%	R	R	Reported
Utilization and Risk Adjusted Utilization					
Well-Child Visits in the First 30 Months of Life (W30)					
(First 15 Months)		63.99%	R	R	Reported
(15 Months-30 Months)		69.63%	R	R	Reported
Child and Adolescent Well-Care Visits (WCV)					
(Total)		51.28%	R	R	Reported
Antibiotic Utilization for Respiratory Conditions (AXR)	Y				
(Total)		26.30%	R	R	Reported
Plan All-Cause Readmissions (PCR)			R	R	Reported
Acute Hospital Utilization (AHU)			R	R	Reported
Health Plan Descriptive Information					
Enrollment by Product Line (ENP)			R	R	Reported
Language Diversity of Membership (LDM)			R	R	Reported
Race/Ethnicity Diversity of Membership (RDM)			R	R	Reported
Measures Reported Using Electronic Clinical Data Systems					
Childhood Immunization Status (CIS-E)					
DTaP		72.75%	R	R	Reported
IPV		86.15%	R	R	Reported
MMR		87.01%	R	R	Reported
HIB		85.15%	R	R	Reported
Hepatitis B		87.63%	R	R	Reported
VZV		86.02%	R	R	Reported
Pneumococcal Conjugate		71.51%	R	R	Reported

Hepatitis A		85.78%	R	R	Reported
Rotavirus		72.42%	R	R	Reported
Influenza		33.42%	R	R	Reported
Combo 3		65.21%	R	R	Reported
Combo 7		59.16%	R	R	Reported
Combo 10		26.91%	R	R	Reported
Immunizations for Adolescents (IMA-E)					
Meningococcal		86.60%	R	R	Reported
Tdap		87.56%	R	R	Reported
HPV		37.67%	R	R	Reported
Combination 1		86.03%	R	R	Reported
Combination 2		37.33%	R	R	Reported
Breast Cancer Screening (BCS-E)					
(Total)		41.42%	R	R	Reported
Documented Assessment After Mammogram (DBM-E)					
Documented Assessment After Mammogram		0.00%	R	R	Reported
Follow-Up After Abnormal Mammogram Assessment (FMA-E)					
Follow-Up After Abnormal Mammogram Assessment			NA	R	Reported
Cervical Cancer Screening (CCS-E)					
Cervical Cancer Screening		43.79%	R	R	Reported
Colorectal Cancer Screening (COL-E)					
(Total)		36.33%	R	R	Reported
Blood Pressure Control for Patients With Hypertension (BPC-E)					
Blood Pressure Control for Patients With Hypertension		47.39%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)	Y				
Initiation Phase		43.72%	R	R	Reported
Continuation and Maintenance Phase		45.53%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)	Y				
Blood Glucose Testing (Total)		62.99%	R	R	Reported
Cholesterol Testing (Total)		42.37%	R	R	Reported
Blood Glucose and Cholesterol Testing (Total)		41.64%	R	R	Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)					
Depression Screening (Total)		21.61%	R	R	Reported
Follow-Up on Positive Screen (Total)		77.63%	R	R	Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)					
Utilization of PHQ-9-Total (Total)		13.17%	R	R	Reported
Depression Remission or Response for Adolescents and Adults (DRR-E)					
Follow-Up PHQ-9 (Total)		36.30%	R	R	Reported
Depression Remission (Total)		7.56%	R	R	Reported
Depression Response (Total)		12.35%	R	R	Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)					
Unhealthy Alcohol Use Screening (Total)		0.58%	R	R	Reported
Alcohol Counseling or Other Follow-Up Care (Total)		25.37%	R	R	Reported
Adult Immunization Status (AIS-E)					
Influenza (Total)		19.07%	R	R	Reported
Td/Tdap (Total)		53.15%	R	R	Reported
Zoster (Total)		19.70%	R	R	Reported
Hepatitis B (Total)		23.34%	R	R	Reported
Pneumococcal (65+)		69.81%	R	R	Reported
Prenatal Immunization Status (PRS-E)					
Influenza		35.01%	R	R	Reported
Tdap		70.29%	R	R	Reported
Combination		31.76%	R	R	Reported
Prenatal Depression Screening and Follow-Up (PND-E)					
Depression Screening		45.42%	R	R	Reported
Follow-Up on Positive Screen		47.06%	R	R	Reported
Postpartum Depression Screening and Follow-Up (PDS-E)					
Depression Screening		41.21%	R	R	Reported
Follow-Up on Positive Screen		54.81%	R	R	Reported
Social Need Screening and Intervention (SNS-E)					
Food Screening (Total)		0.00%	R	R	Reported
Food Intervention (Total)			NA	R	Reported
Housing Screening (Total)		0.00%	R	R	Reported
Housing Intervention (Total)			NA	R	Reported
Transportation Screening (Total)		0.00%	R	R	Reported
Transportation Intervention (Total)			NA	R	Reported